title: Extended duration of the detectable stage by adding HPV test in cervical cancer screening.
abstract: The human papillomavirus test (HPV) test could improve the (cost-) effectiveness of cervical screening by selecting women with a very low risk for cervical cancer during a long period. An analysis of a longitudinal study suggests that women with a negative Pap smear and a negative HPV test have a strongly reduced risk of developing cervical abnormalities in the years following the test, and that HPV testing lengthens the detectable stage by 2-5 years, compared to Pap smear detection alone.
authors: Department of Public Health, Erasmus MC, PO Box 1738, 3000 DR Rotterdam, The Netherlands. vandenakkervanmarie@pg.tno.nl
authors: M E
authors: ME
authors: van den Akker-van Marie
authors: M
authors: M
authors: van Ballegooijen
authors: L
authors: L
authors: Rozendaal
authors: C J L M
authors: CJ
authors: Meijer
authors: J D F
authors: JD
authors: Habbema
mesh_terms: D000328:Adult; D005260:Female; D006801:Humans; D008403:Mass Screening; D008875:Middle Aged; D009367:Neoplasm Staging; D065006:Papanicolaou Test; D027383:Papillomaviridae / Q000472:pathogenicity*; D030361:Papillomavirus Infections / Q000150:complications / Q000175:diagnosis*; D012307:Risk Factors; D012680:Sensitivity and Specificity; D014412:Tumor Virus Infections / Q000150:complications / Q000175:diagnosis*; D002583:Uterine Cervical Neoplasms / Q000175:diagnosis* / Q000821:virology*; D014626:Vaginal Smears; D002578:Uterine Cervical Dysplasia / Q000175:diagnosis / Q000821:virology